Navigation Links
Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY

- Study shows orally-delivered GLP-1 is able to stimulate insulin release

TARRYTOWN, N.Y., March 29, 2007 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. reported today results of two clinical studies conducted in collaboration with Professor Christoph Beglinger, M.D. Division of Gastroenterology and Hepatology, University Hospital Basel in Basel, Switzerland. The objective of the study with glucagon-like peptide-1 (7-36 amide) (GLP-1) was to establish the initial pharmacological profile and the insulin releasing activity of increasing oral doses of GLP-1 in healthy volunteers. In addition, the pharmacokinetic effects of GLP-1 were investigated after intravenous administration. The objective of the study with peptide YY 3-36 (PYY) was to establish the PYY plasma concentrations following increasing oral doses of the peptide.

The results showed that Emisphere's eligen(R) technology can orally deliver the incretin hormones GLP-1 and PYY. The oral administration of both peptides induced a rapid and dose-dependent, statistically significant increase in plasma drug concentrations (p<0.05) at all doses tested versus placebo. Additionally, the orally delivered GLP-1 induced a statistically significant effect on insulin release in all healthy male volunteers (p<0.05) at all doses tested versus placebo. The Company expects these results to be published in a leading peer-reviewed scientific journal later this year.

GLP-1 was given orally to six healthy male subjects in a six way cross-over design. The treatment arms consisted of oral doses of GLP-1 (0.5, 1.0, 2.0 and 4.0 mg of drug) with Emisphere's delivery agent administered as a single tablet versus placebo. Only one dose was given per day. On a separate day, subjects received an intravenous infusion of GLP-1 (0.4 pMol/kg/min infused for 45 minutes). Blood samples were obtained for GLP-1 and insulin concentrations. The Cmax plasma concentration for
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/2/2008)...ire/ -- Horizon Therapeutics, Inc., a,privately h...t two pivotal,Phase 3 trials evaluating its lead ...ll primary endpoints. HZT-501, a novel, proprietar...ofen and famotidine, demonstrated a,statistically...roidal,anti-inflammatory drug (NSAID)-induced upp...
(Date:12/1/2008)...c. 2 A study has found ...chnique for imaging the breast, is not affected by...s, two factors that limit the effectiveness of sta...ults will be presented today at the annual meeting...A). , , "The ability of PEM to detect canc...
(Date:12/1/2008).../ -- S*BIO Pte Ltd today announced the initiation ...and orally-active JAK2 inhibitor, in leading medic...idiopathic myelofibrosis (CIMF). , , The t...bility of SB1518 in patients with CIMF and is expe... of the study will assess the safety profile and e...
(Date:12/1/2008)...1 gene is a two-way switch that, if turned off, ca...d so that they lose their identity and become more...Tenn., Dec. 1 Scientis...iscovered that a certain differentiated cell type ...s the constant expression of a gene called Prox1 ...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 1Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 2SI International Awarded 244 Million Army HRsolutions Task Order 3781 1SI International Awarded 244 Million Army HRsolutions Task Order 3781 2SI International Awarded 244 Million Army HRsolutions Task Order 3781 3Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 1Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 2CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 1CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 2CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 3CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 4
...oequivalent Pharmacokinetics With Reduced Risk,of ..., April 25, 2007 /PRNewswire-FirstCall/ -- ADVENTR...arch and,development company focused on commercial...ment of cancer and infectious diseases,today anno...netic,testing of ANX-514 (docetaxel emulsion) in a...
..., April 25, 2007 - Basilea Pharmaceutica Ltd.,(SWX...ing that,patients with severe chronic hand eczema ...n two previous randomized clinical,trials, alitret...,chronic hand eczema in patients refractory to top...hat patients responsive to initial,treatment with ...
Other Medicine Technology:ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 2ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 3ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 4ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 5Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5
(Date:12/2/2008)... ORLANDO, Fla., Dec. 2 MEDai, Inc...care solutions provider, has added a new module,t...ons. The new stand-alone,module monitors a popul...delines and alerts stakeholders when there has bee...e Risk Navigator Guidelines(TM) provides,real-tim...
(Date:12/2/2008)... CHICAGO, Dec. 2 MedCommons annou...the EMC Open Systems Archive Solution for Healthca...lution for Healthcare,Organizations provides a mo...gregates and reconciles patient information, inclu...plications into a patient-centric archive. The,in...
(Date:12/2/2008)... VANCOUVER, Dec. 2 /PRNewswire-FirstCall/ - Respo...) announced the initiation of a clinical trial of ...yncytial Virus (RSV). Prospective data from the cl...ubmission to the U.S. Food and Drug Administration...et clearance of the 3M Rapid Detection RSV test fo...
(Date:12/2/2008)... At Least 10 New Cellular Therapies Will Launch O...cision Resources , , WALTHAM, Mass., Dec. 2...rld,s leading research and advisory firms for phar...ellular therapies drug market will experience robu...e, reaching $1.5 billion in 2017. According to the...
Breaking Medicine News(10 mins):Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 2Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 3Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 2Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 3Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 4Health News:Market for Cellular Therapies Will Grow at a Robust Annual Rate of More Than 30 Percent in the United States Through 2017 2
... from LaTrobe University of Australia have found a...ciparum, the parasite responsible for causing mala...imaquine for treatment // helps in killing P. falc...ne drug. Chloroquine is a largely used drug in the...
...avoidance is the only way to prevent food allergy,...ions. Although an individual could be allergic to ...he following // eight foods i.e. cow’s milk, egg, ...ellfish, legumes (peanut and soy), cereals (wheat,...
...ne of the most common breathing problems encounter..., there has been a considerable increase in the in...n. // It has been estimated that nearly 196,000 ch...States every year with asthma attacks. A considera...
...atent rows over basmati and turmeric, India doesn'... certainly not when it comes to its ancient healin...task force appointed by the government for protect...tual property is fast completing the documentation...
Other Medicine News:Health News:Improved parent-physician communication to prevent hospitalizations for childhood asthma 2Health News:Yoga, ayurveda being documented to stop patent misuse 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: